MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Matched conditions: MYELOFIBROSIS
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo aims to improve myelofibrosis treatment
Disease control Not yet recruitingThis early-phase study tests whether adding the drug ropeginterferon alfa-2b to the standard treatment ruxolitinib is safe for people with myelofibrosis, a type of bone marrow cancer. About 15 adults already on a stable dose of ruxolitinib will receive the combination. The main g…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to shrink spleen in Hard-to-Treat myelofibrosis
Disease control Not yet recruitingThis phase II trial tests two oral drugs, selinexor and pacritinib, in 26 adults with myelofibrosis who have anemia and low platelets and have not taken JAK inhibitors before. The main goal is to see if the combination can shrink the spleen by at least 35%. The study also tracks …
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy aims to shrink enlarged spleens in bone marrow cancer patients
Disease control Not yet recruitingThis study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a type of bone marrow cancer. It is for patients whose spleen is still enlarged after 12 weeks on momelotinib alone. The main goal is to see if the combination reduces…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: United Lincolnshire Hospitals NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC